Company intelligence / Profile preview

Morphogen-IX

Babraham, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Morphogen-IX developed a novel disease-modifying therapeutic aimed at the underlying causes of pulmonary arterial hypertension by targeting bone morphogenetic protein pathways; it was acquired by Centessa Pharmaceuticals in January 2021[4].

Therapeutic areas: Cardiovascular
Modalities: Small moleculeProtein (specifically recombinant bone morphogenetic proteins)
Industry: Biotech

Partnerships

Privileged relationship with University of Cambridge[4]

Beyond the preview

Go deeper on Morphogen-IX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Morphogen-IX.

Explore the full profile